Skip to content Skip to main menu

Pipelines

Our Microbiome Determines balanced health

Non-Invasive In Vitro Diagnostics

Paradigm Shift in Cancer Therapeutics

Diagnostic Method:

invasive → noninvasive
tissue biopsy → liquid biopsy

Liquid Biopsy Biomarkers

Circulation tumor cells →
Cell-free DNA (cfDAA), especially
extracellular vesicles (EVs)

MD Healthcare Diagnostic Capabilities

Urine Diagnosis

Hepatic Cancer, Ovary Cancer,
Lung Cancer, Colorectal Cancer,
Stomach Cancer, Breast Cancer,
Prostate Cancer, Pancreatic Cancer

Stool Diagnosis

Colorectal Cancer, Stomach Cancer,
Inflammatory Boewl Disease

PCR-based diagnostic Pipeline Milestone

Polymerase chain-reaction (PCR) technology can be utilized as a diagnostic method to assess disease risk through assessment of DNA biomarkers in our bodies.
We discovered through microbiome analysis of thousands of healthy and patient samples that microbial EVs are powerful biomarkers that can be assessed in both stool and urine. Using bioinformatic analysis, we are developing diagnostic algorithms based on quantification of multiple biomarkers to calculate disease risk for a variety of chronic diseases using affordable and accessible PCR echnology. Our PCR diagnostic kits and software packages are ideal for fast, accurate risk assessment in hospitals, public institutions, and research facilities.


As of Aug. 2019

Non-clinical Clinical

NGS-based diagnostic Pipeline Milestone

Next-generation sequencing (NGS) technology provides ultra-high throughput and fast assessment of all DNA sequences present in a sample. This robust technology is ideal for the development of highly accurate diagnosis of chronic illnesses that require sensitive, system-level analysis. By comparing the EV microbiome of thousands of patient and healthy samples, we are developing algorithms to determine risk of a variety of chronic diseases in stool, urine, and blood samples using NGS technology. Our NGS software packages are ideal for high throughput risk assessment of chronic disease in hospitals, public institutions, and research facilities.


As of Aug. 2019

Non-clinical Clinical